Source: International Congress 2019 – Asthma treatment: novel insights from clinical studies
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Y. Ye (Oxford, United Kingdom), R. Shrimanker (Oxford, United Kingdom), P. Batty (Oxford, United Kingdom), K. Borg (Oxford, United Kingdom), C. Connolly (Oxford, United Kingdom), S. Thulborn (Oxford, United Kingdom), J. Cane (Oxford, United Kingdom), G. Hynes (Oxford, United Kingdom), T. Hinks (Oxford, United Kingdom), J. Steiner (Oxford, United Kingdom), S. Vinall (Abingdon, United Kingdom), M. Hunter (Abingdon, United Kingdom), R. Pettipher (Abingdon, United Kingdom), L. Xue (Oxford, United Kingdom), I. Pavord (Oxford, United Kingdom). Late Breaking Abstract - An assessment of potential predictive biomarkers for the treatment of severe eosinophilic asthma with CRTH2 antagonists. 3708

Member's Comments

No comment yet.

Related content which might interest you: Late Breaking Abstract - Effect of timapiprant, a DP2 antagonist, on airway inflammation in severe eosinophilic asthma Source: International Congress 2019 – ALERT: Abstracts Leading to Evolution in Respiratory Medicine Trials: Asthma Year: 2019 Late Breaking Abstract - The impact of treatment with mepolizumab on airway remodeling in patients with severe eosinophilic asthma. Source: Virtual Congress 2021 – Asthma clinical trials and real-life studies Year: 2021 Late Breaking Abstract - Clinical characteristics and lung function trends of severe eosinophilic asthma patients unresponsive to Mepolizumab Source: International Congress 2019 – Blood eosinophils and more in airway diseases Year: 2019 Late Breaking Abstract - Multiple ascending dose study of the inhaled IL-4Ra antagonist, AZD1402/PRS-060, in mild asthmatics demonstrates robust FeNO reduction and a promising clinical profile for the treatment of asthma Source: International Congress 2019 – Asthma treatment: novel insights from clinical studies Year: 2019 Late Breaking Abstract - Benralizumab treatment strongly reduces blood basophils in patients with severe eosinophilic asthma Source: International Congress 2019 – Understanding, monitoring and targeting severe asthma Year: 2019 Late Breaking Abstract - Phase 2 trial evaluating the effects of dexpramipexole on blood eosinophils, lung function, and airway biomarkers in eosinophilic asthma Source: Virtual Congress 2021 – ALERT: Asthma in adult, in children and ILDs Year: 2021 Immunocytochemistry evaluation of FKBP51 in induced sputum cells as a biomarker of glucocorticoid therapy in asthma Source: International Congress 2015 – Exploring mechanisms in obstructive airway diseases Year: 2015 Upregulation of interleukin-19 in severe asthma: a potential saliva biomarker for asthma severity Source: ERJ Open Res, 7 (3) 00984-2020; 10.1183/23120541.00984-2020 Year: 2021 Measuring inflammation inpaediatric severe asthma: biomarkers in clinical practice Source: Breathe, 16 (1) 190301; 10.1183/20734735.0301-2019 Year: 2020 Late Breaking Abstract: Inhaled pitrakinra, an IL-4/IL-13 antagonist, reduced exacerbations in patients with eosinophilic asthma Source: Annual Congress 2010 - Treatment options for asthma Year: 2010 Late Breaking Abstract - Effect of inhaled corticosteroids on exacerbation of asthma–COPD overlap according to different diagnostic criteria Source: International Congress 2019 – COPD clinical studies: bronchodilators, corticosteroids and more Year: 2019 TH2 specific biomarker profile determines steroid responsiveness in severe asthma Source: Annual Congress 2013 –Biomarkers in asthma and COPD Year: 2013 Late Breaking Abstract - The blood eosinophils count as a predictor of the response for omalizumab (OMA) in patients suffering from severe allergic asthma Source: International Congress 2019 – Blood eosinophils and more in airway diseases Year: 2019 Late Breaking Abstract - PK/PD assessment of an oral, selective aVß6/aVß1 integrin dual antagonist, PLN-74809, for the treatment of idiopathic pulmonary fibrosis Source: International Congress 2019 – Translational aspects of idiopathic interstitial pneumonia Year: 2019 Markers of eosinophilic airway inflammation in patients with severe and mild to moderate asthma Source: International Congress 2016 – Airway biomarkers Year: 2016 Late Breaking Abstract - Early response to benralizumab in Canadians with severe eosinophilic asthma Source: Virtual Congress 2021 – Asthma clinical trials and real-life studies Year: 2021 Late Breaking Abstract - Patients with severe eosinophilic asthma benefit from the treatment with Anti-IL-5 Reslizumab – a real life study from Austria Source: International Congress 2018 – Notable Studies in Asthma Year: 2018 Markers of eosinophilic inflammation are associated with response to the DP2 antagonist GB001 in patients with mild atopic asthma Source: International Congress 2019 – Asthma treatment: novel insights from clinical studies Year: 2019 Late Breaking Abstract - Daily physical activity in patients with severe eosinophilic asthma and the effect of anti-IL5 therapy. Source: International Congress 2018 – New pharmacological strategies in airway diseases Year: 2018 Late Breaking Abstract - Anti-IL-5 mepolizumab minimally influences residual blood eosinophils in severe asthma Source: Virtual Congress 2021 – Asthma clinical trials and real-life studies Year: 2021